Niki BioSolutions’ Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” Series
Globe Newswire•16/10/2026•08:00 ET
0
Key Highlights
- ➤Niki’s Rett biomarker panel features 44 blood-detectable microRNAs enriched in affected organs
- ➤Panel evaluated in blood samples from over 200 individuals across two clinical studies
- ➤IRSF selected DiamiR for its “Rett Research Tool Belt” research technology series
- ➤Program targets minimally invasive monitoring of Rett syndrome severity, progression, and treatment response
Expert Statements
Kira Sheinerman, Co-founder of DiamiR and Director of Niki BioSolutions
“The need for accurate, minimally invasive biomarkers capable of monitoring Rett syndrome severity, progression, and potential response to treatment, including in clinical trials.”
Alidad Mireskandari, Chief Operating Officer and President of Niki BioSolutions
“As new Rett syndrome therapies advance through clinical development, we believe objective, minimally invasive biomarkers could become increasingly valuable tools by providing researchers and clinicians with effective molecular solutions for evaluating and monitoring disease severity, progression, and response to treatment.”
Alidad Mireskandari, Chief Operating Officer and President of Niki BioSolutions
“Our Rett syndrome program illustrates the potential of Niki’s biomarker technology to address unmet needs in drug development, as well as its utility in clinical research and planning of care. We appreciate the IRSF’s continued opportunities to share this work with the Rett syndrome research community.”
Company’s blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome
Access the “Rett Research Tool Belt” at https://www.rettsyndrome.org/toolbelt-biomarkers/
Get started
Create a free account to read the full story.